EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung study Multiple cl ...

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV ("Janssen") expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data from Study 1100, and d ...

_____________________________________________________________________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 x for the fiscal y ...

Laurent Levy Hi. Thank you for taking my question. I had one for the pancreatic cancer study. How comparable are the baseline characteristics of the patients into previous MD studies? And the patients in the ongoing Phase 1, for instance, in terms of level of CA19-9 at diagnosis? And could you give us the amplitude of reduction of that biomarker levels observed in your study? the RP2D. So, the enrollment continues to be good in this trial. It's just slightly delayed versus what was initially planned. But al ...

• Cash balance as of September 30, 2023: €38.7 million • Closing of recent financing result(ed) in gross proceeds of €50.9 million • EIB cash covenant removed • This excludes any further dilutive (incl. use of equity line) or non-dilutive financing, and includes a first de- risked milestones from NBTXR3 collaboration • Cash Runway is expected to extend to end of Q2 25 upon completion of remaining amount of €4.6 million of €23.7 million ($25 million) second tranche commitment of JJDC, subject to closing cond ...

Nanobiotix S.A. (NASDAQ:NBTX) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference Call Participants Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by. Welcome to the Nanobiotix Business Update and First Half 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakerÂ's ...

Nanobiotix S.A. (NASDAQ:NBTX) Q4 2022 Results Conference Call April 25, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Miller - Evercore ISI Elliott Bosco - UBS Swayampakula Ramakanth - H.C. Wainwright Clément Bassat - BNP Paribas Operator Good day, and thank you for standing by. Welcome to the Nanobiotix business update and full-year 2022 financial results conference call. A slide presentation accompanyi ...

_____________________________________________________________________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 x for the fiscal y ...

Nanobiotix S.A. (NASDAQ:NBTX) Q3 2022 Earnings Call Transcript November 10, 2022 8:00 AM ET Company Participants Kate Mcneil - Senior Vice President, Investor Relations Laurent Levy - Co-Founder & Chief Executive Officer Bart Van Rhijn - Chief Financial Officer Conference Call Participants Mike DiFiore - Evercore Cl??ment Bassat - BNP Paribas Kate Mcneil Thank you, operator. Good afternoon and good morning, and welcome to Nanobiotix Conference Call to discuss our Third Quarter 2022 Financial and Operational ...

Nanobiotix S.A (NASDAQ:NBTX) Q2 2022 Earnings Conference Call September 29, 2022 8:00 AM ET Company Participants Laurent Levy - Co-Founder, CEO Bart Van Rhijn - CFO Kate McNeil - IR Conference Call Participants Jon Miller - Evercore Suzanne van Voorthuizen - Kempen Kate McNeil Good afternoon and good morning. And welcome to Nanobiotix Conference Call to discuss our First Half 2022 Financial and Operational results. Joining me in the call today, are Laurent Levy, co-Founder and Chief Executive Officer and Ba ...